Find Research outputs

Search results

• Phase i studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

  Cortes, J., Tamura, K., Deangelo, D. J., De Bono, J., Lorente, D., Minden, M., Uy, G. L., Kantarjian, H., Chen, L. S., Gandhi, V., Godin, R., Keating, K., McEachern, K., Vishwanathan, K., Pease, J. E. & Dean, E., May 1 2018, In: British Journal of Cancer. 118, 11, p. 1425-1433 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  29 Scopus citations

• Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

  Ghanem, H., Kantarjian, H., Cortes, J., Quintás-Cardama, A. & Jabbour, E., 2013, In: Expert Opinion on Orphan Drugs. 1, 8, p. 607-623 17 p.

  Research output: Contribution to journal › Review article › peer-review

• Phase II trial of web-based tailored asthma management intervention in adolescents at clinics

  Lu, M., Zhang, T., Ownby, D. R., Zoratti, E., Johnson, D. A., William, R., Miree, C. & Joseph, C. L. M., Jul 2019, In: Contemporary Clinical Trials. 82, p. 46-52 7 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

  Garcia-Manero, G., Tambaro, F. P., Bekele, N. B., Yang, H., Ravandi, F., Jabbour, E., Borthakur, G., Kadia, T. M., Konopleva, M. Y., Faderl, S., Cortes, J. E., Brandt, M., Hu, Y., McCue, D., Newsome, W. M., Pierce, S. R., De Lima, M. & Kantarjian, H. M., Jun 20 2012, In: Journal of Clinical Oncology. 30, 18, p. 2204-2210 7 p.

  Research output: Contribution to journal › Article › peer-review
  125 Scopus citations

• Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

  Zakharia, Y., McWilliams, R. R., Rixe, O., Drabick, J., Shaheen, M. F., Grossmann, K. F., Kolhe, R., Pacholczyk, R., Sadek, R., Tennant, L. L., Smith, C. M., Kennedy, E. P., Link, C. J., Vahanian, N. N., Yu, J., Shen, S. S., Brincks, E. L., Rossi, G. R., Munn, D. & Milhem, M., Jun 11 2021, In: Journal for ImmunoTherapy of Cancer. 9, 6, e002057.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  1 Scopus citations

• Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

  Jazieh, A. R., Komrokji, R., Gupta, A., Patil, S., Flora, D., Knapp, M., Issa, M. & Abdel Karim, N. F. M., Oct 22 2009, In: Cancer Investigation. 27, 9, p. 932-936 5 p.

  Research output: Contribution to journal › Article › peer-review
  11 Scopus citations

• Phase-II trial of tamoxifen in advanced breast cancer

  Wiggans, R. G., Woolley, P. V., Smythe, T., Hoth, D., Macdonald, J. S., Green, L. & Schein, P. S., Aug 1979, In: Cancer Chemotherapy and Pharmacology. 3, 1, p. 45-48 4 p.

  Research output: Contribution to journal › Article › peer-review
  24 Scopus citations

• Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

  Wiggans, R. G., Woolley, P. V., Macdonald, J. S., Smythe, T., Ueno, W. & Schein, P. S., Feb 1978, In: Cancer. 41, 2, p. 387-391 5 p.

  Research output: Contribution to journal › Article › peer-review
  87 Scopus citations

• Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

  Sanford, D., Kantarjtan, H., Skinner, J., Jabbour, E. & Cortes, J., 2015, In: Haematologica. 100, 12, p. e494-e495

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  15 Scopus citations

• Phase II Trial of Murine Monoclonal Antibody D612 Combined with Recombinant Human Monocyte Colony-stimulating Factor (rhM-CSF) in Patients with Metastatic Gastrointestinal Cancer

  Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Liu, T., Everson, M. P., LoBuglio, A. F., Bucy, R. P., Schlom, J. & Munn, D. H., Oct 1 1995, In: Cancer Research. 55, 19, p. 4339-4346 8 p.

  Research output: Contribution to journal › Article › peer-review
  14 Scopus citations

• Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

  Maiti, A., Naqvi, K., Kadia, T. M., Borthakur, G., Takahashi, K., Bose, P., Daver, N. G., Patel, A., Alvarado, Y., Ohanian, M., DiNardo, C. D., Cortes, J. E., Jabbour, E. J., Garcia-Manero, G., Kantarjian, H. M. & Ravandi, F., Mar 2019, In: Clinical Lymphoma, Myeloma and Leukemia. 19, 3, p. 142-148.e1

  Research output: Contribution to journal › Article › peer-review
  15 Scopus citations

• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

  Lin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van Den Abbeele, A. D., Henson, J. W., Li, X., Gelman, R., Burstein, H. J., Kasparian, E., Kirsch, D. G., Crawford, A., Hochberg, F. & Winer, E. P., 2008, In: Journal of Clinical Oncology. 26, 12, p. 1993-1999 7 p.

  Research output: Contribution to journal › Article › peer-review
  357 Scopus citations

• Phase II trial of interleukin 1α and indomethacin in treatment of metastatic melanoma

  Janik, J. E., Miller, L. L., Longo, D. L., Powers, G. C., Urba, W. J., Kopp, W. C., Gause, B. L., Curti, B. D., Fenton, R. G., Oppenheim, J. J., Conlon, K. C., Holmlund, J. T., Sznol, M., Sharfman, W. H., Steis, R. G., Creekmore, S. P., Alvord, W. G., Beauchamp, A. E. & Smith, J. W., 1996, In: Journal of the National Cancer Institute. 88, 1, p. 44-49 6 p.

  Research output: Contribution to journal › Article › peer-review
  24 Scopus citations

• Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma

  Salman, H., Perez, A., Sparano, J. A., Ratech, H., Negassa, A., Hopkins, U., Villani, G., Fuks, J. & Wiernik, P. H., Aug 1 2003, In: American Journal of Clinical Oncology: Cancer Clinical Trials. 26, 4, p. 338-343 6 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

  Benjamini, O., Dumlao, T. L., Kantarjian, H., O'Brien, S., Garcia-Manero, G., Faderl, S., Jorgensen, J., Luthra, R., Garris, R., Thomas, D., Kebriaei, P., Champlin, R., Jabbour, E., Burger, J., Cortes, J. & Ravandi, F., Mar 2014, In: American Journal of Hematology. 89, 3, p. 282-287 6 p.

  Research output: Contribution to journal › Article › peer-review
  43 Scopus citations

• Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

  Maiti, A., Cortes, J., Ferrajoli, A., Estrov, Z., Borthakur, G., Garcia-Manero, G., Jabbour, E., Ravandi, F., O’Brien, S. & Kantarjian, H., Sep 2 2017, In: Leukemia and Lymphoma. 58, 9, p. 2240-2242 3 p.

  Research output: Contribution to journal › Letter › peer-review
  3 Scopus citations

• Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

  Issa, G. C., Kantarjian, H. M., Xiao, L., Ning, J., Alvarado, Y., Borthakur, G., Daver, N., DiNardo, C. D., Jabbour, E., Bose, P., Jain, N., Kadia, T. M., Naqvi, K., Pemmaraju, N., Takahashi, K., Verstovsek, S., Andreeff, M., Kornblau, S. M., Estrov, Z., Ferrajoli, A. & 5 others, Garcia-Manero, G., Ohanian, M., Wierda, W. G., Ravandi, F. & Cortes, J. E., Nov 1 2020, In: Leukemia. 34, 11, p. 2914-2924 11 p.

  Research output: Contribution to journal › Article › peer-review
  3 Scopus citations

• Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

  Giles, F. J., Feldman, E. J., Roboz, G. J., Larson, R. A., Mamus, S. W., Cortes, J. E., Verstovsek, S., Faderl, S., Talpaz, M., Beran, M., Albitar, M., O'Brien, S. M. & Kantarjian, H. M., Dec 1 2003, In: Leukemia Research. 27, 12, p. 1091-1096 6 p.

  Research output: Contribution to journal › Article › peer-review
  20 Scopus citations

• Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

  Giles, F. J., Garcia-Manero, G., Cortes, J. E., Baker, S. D., Miller, C. B., O'Brien, S. M., Thomas, D. A., Andreeff, M., Bivins, C., Jolivet, J. & Kantarjian, H. M., Feb 1 2002, In: Journal of Clinical Oncology. 20, 3, p. 656-664 9 p.

  Research output: Contribution to journal › Article › peer-review
  70 Scopus citations

• Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

  Matulonis, U., Vergote, I., Backes, F., Martin, L. P., McMeekin, S., Birrer, M., Campana, F., Xu, Y., Egile, C. & Ghamande, S. A., Feb 1 2015, In: Gynecologic Oncology. 136, 2, p. 246-253 8 p.

  Research output: Contribution to journal › Article › peer-review
  70 Scopus citations

• Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

  Kesari, S., Schiff, D., Henson, J. W., Muzikansky, A., Gigas, D. C., Doherty, L., Batchelor, T. T., Longtine, J. A., Ligon, K. L., Weaver, S., Laforme, A., Ramakrishna, N., Black, P. M. L., Drappatz, J., Ciampa, A., Folkman, J., Kieran, M. & Wen, P. Y., Jun 2008, In: Neuro-Oncology. 10, 3, p. 300-308 9 p.

  Research output: Contribution to journal › Article › peer-review
  67 Scopus citations

• Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

  Thomas, D. A., Sarris, A. H., Cortes, J., Faderl, S., O'Brien, S., Giles, F. J., Garcia-Manero, G., Rodriguez, M. A., Cabanillas, F. & Kantarjian, H., Jan 1 2006, In: Cancer. 106, 1, p. 120-127 8 p.

  Research output: Contribution to journal › Article › peer-review
  62 Scopus citations

• Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

  Garg, R., Faderl, S., Garcia-Manero, G., Cortes, J., Koller, C., Huang, X., York, S., Pierce, S., Brandt, M., Beran, M., Borthakur, G., Kantarjian, H. & Ravandi, F., 2009, In: Leukemia. 23, 7, p. 1297-1302 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  38 Scopus citations

• Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

  Kurzrock, R., Albitar, M., Cortes, J. E., Estey, E. H., Faderl, S. H., Garcia-Manero, G., Thomas, D. A., Giles, F. J., Ryback, M. E., Thibault, A., De Porre, P. & Kantarjian, H. M., Dec 1 2004, In: Journal of Clinical Oncology. 22, 7, p. 1287-1292 6 p.

  Research output: Contribution to journal › Article › peer-review
  144 Scopus citations

• Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

  Daver, N., Shastri, A., Kadia, T., Newberry, K., Pemmaraju, N., Jabbour, E., Zhou, L., Pierce, S., Cortes, J., Kantarjian, H. & Verstovsek, S., Sep 2014, In: Leukemia Research. 38, 9, p. 1126-1129 4 p.

  Research output: Contribution to journal › Article › peer-review
  26 Scopus citations

• Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

  Matulonis, U. A., Sharma, S., Ghamande, S. A., Gordon, M. S., Del Prete, S. A., Ray-Coquard, I., Kutarska, E., Liu, H., Fingert, H., Zhou, X., Danaee, H. & Schilder, R. J., Oct 2012, In: Gynecologic Oncology. 127, 1, p. 63-69 7 p.

  Research output: Contribution to journal › Article › peer-review
  110 Scopus citations

• Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

  Kadia, T. M., Kantarjian, H. M., Thomas, D. A., O'Brien, S., Estrov, Z., Ravandi, F., Jabbour, E., Pemmaraju, N., Daver, N., Wang, X., Jain, P., Pierce, S., Brandt, M., Garcia-Manero, G., Cortes, J. & Borthakur, G., Feb 1 2015, In: American Journal of Hematology. 90, 2, p. 120-124 5 p.

  Research output: Contribution to journal › Article › peer-review
  15 Scopus citations

• Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

  Issa, J. P. F., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G. & Kantarjian, H. M., 2005, In: Journal of Clinical Oncology. 23, 17, p. 3948-3956 9 p.

  Research output: Contribution to journal › Article › peer-review
  254 Scopus citations

• Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

  Oki, Y., Kantarjian, H. M., Gharibyan, V., Jones, D., O'Brien, S., Verstovsek, S., Cortes, J., Morris, G. M., Garcia-Manero, G. & Issa, J. P. J., Mar 1 2007, In: Cancer. 109, 5, p. 899-906 8 p.

  Research output: Contribution to journal › Article › peer-review
  110 Scopus citations

• Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

  Vega-Ruiz, A., Cortes, J. E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H. M. & Verstovsek, S., Nov 2009, In: Leukemia Research. 33, 11, p. 1481-1484 4 p.

  Research output: Contribution to journal › Article › peer-review
  106 Scopus citations

• Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

  Tsimberidou, A. M., O'Brien, S. M., Cortes, J. E., Faderl, S., Andreeff, M., Kantarjian, H. M., Keating, M. J. & Giles, F. J., 2002, In: Leukemia and Lymphoma. 43, 4, p. 767-772 6 p.

  Research output: Contribution to journal › Article › peer-review
  49 Scopus citations

• Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

  Wilson, W. H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S. M., Raffeld, M., Gutierrez, M., Chabner, B. A., Staudt, L., Jaffe, E. S. & Janik, J. E., 2008, In: Journal of Clinical Oncology. 26, 16, p. 2717-2724 8 p.

  Research output: Contribution to journal › Article › peer-review
  235 Scopus citations

• Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis

  Verstovsek, S., Tefferi, A., Cortes, J., O'Brien, S., Garcia-Manero, G., Pardanani, A., Akin, C., Faderl, S., Manshouri, T., Thomas, D. & Kantarjian, H., Jun 15 2008, In: Clinical Cancer Research. 14, 12, p. 3906-3915 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  141 Scopus citations

• Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer

  Mott, F. E., Cable, C. T. & Sharma, N., Nov 2003, In: Clinical Lung Cancer. 5, 3, p. 174-176 3 p.

  Research output: Contribution to journal › Article › peer-review
  8 Scopus citations

• Phase II study of alemtuzumab in chronic lymphoproliferative disorders

  Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A., Faderl, S., Kurzrock, R., Lerner, S., Kontoyiannis, D. P. & Keating, M. J., Aug 15 2003, In: Cancer. 98, 4, p. 773-778 6 p.

  Research output: Contribution to journal › Article › peer-review
  120 Scopus citations

• Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma

  Sharma, K., Janik, J. E., O'Mahony, D., Stewart, D., Pittaluga, S., Stetler-Stevenson, M., Jaffe, E. S., Raffeld, M., Fleisher, T. A., Lee, C. C., Steinberg, S. M., Waldmann, T. A. & Morris, J. C., Jan 1 2017, In: Clinical Cancer Research. 23, 1, p. 35-42 8 p.

  Research output: Contribution to journal › Article › peer-review
  21 Scopus citations

• Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

  Chacar, C., Jabbour, E., Ravandi, F., Borthakur, G., Kadia, T., Estrov, Z., Rios, M. B., Cortes, J. & Kantarjian, H., Jun 2012, In: Clinical Lymphoma, Myeloma and Leukemia. 12, 3, p. 197-200 4 p.

  Research output: Contribution to journal › Article › peer-review
  3 Scopus citations

• Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study

  Cortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D. W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., Moiraghi, B., Rowe, J. M., Tothova, E., De Souza, C., Rudoltz, M., Yu, R., Krahnke, T., Kantarjian, H. M., Radich, J. P. & Hughes, T. P., Jan 20 2010, In: Journal of Clinical Oncology. 28, 3, p. 424-430 7 p.

  Research output: Contribution to journal › Article › peer-review
  218 Scopus citations

• Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

  Sasaki, K., Gotlib, J. R., Mesa, R. A., Newberry, K. J., Ravandi, F., Cortes, J. E., Kelly, P., Kutok, J. L., Kantarjian, H. M. & Verstovsek, S., Jul 1 2015, In: Leukemia and Lymphoma. 56, 7, p. 2092-2097 6 p.

  Research output: Contribution to journal › Article › peer-review
  42 Scopus citations

• Phase II clinical trial of gefitinib for the treatment of chemonaïve patients with advanced non-small cell lung cancer with poor performance status

  Karim, N. A., Musaad, S., Zarzour, A., Patil, S. & Jazieh, A. R., Nov 25 2014, In: Clinical Medicine Insights: Oncology. 8, p. 121-128 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  4 Scopus citations

• Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability

  Berry, J. D., Paganoni, S., Atassi, N., Macklin, E. A., Goyal, N., Rivner, M., Simpson, E., Appel, S., Grasso, D. L., Mejia, N. I., Mateen, F., Gill, A., Vieira, F., Tassinari, V. & Perrin, S., Dec 2017, In: Muscle and Nerve. 56, 6, p. 1077-1084 8 p.

  Research output: Contribution to journal › Article › peer-review
  16 Scopus citations

• Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine

  Badar, T., Cortes, J., Borthakur, G., O'Brien, S., Wierda, W., Garcia-Manero, G., Ferrajoli, A., Kadia, T., Poku, R., Kantarjian, H. & Mattiuzzi, G., Jan 15 2015, In: BioMed Research International. 2015, 497597.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  5 Scopus citations

• Phase II, multicenter, randomized trial of CPX-351 (cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

  Cortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., Kantarjian, H., Louie, A. C. & Kolitz, J. E., Jan 15 2015, In: Cancer. 121, 2, p. 234-242 9 p.

  Research output: Contribution to journal › Article › peer-review
  117 Scopus citations

• Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

  Verstovsek, S., Tam, C. S., Wadleigh, M., Sokol, L., Smith, C. C., Bui, L. A., Song, C., Clary, D. O., Olszynski, P., Cortes, J., Kantarjian, H. & Shah, N. P., Mar 2014, In: Leukemia Research. 38, 3, p. 316-322 7 p.

  Research output: Contribution to journal › Article › peer-review
  37 Scopus citations

• Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-α-2a with and without cytarabine in patients with chronic myelogenous leukemia

  Talpaz, M., Rakhit, A., Rittweger, K., O'Brien, S., Cortes, J., Fettner, S., Hooftman, L. & Kantarjian, H., Sep 1 2005, In: Clinical Cancer Research. 11, 17, p. 6247-6255 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  29 Scopus citations

• Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer

  Ward, R. L., Packham, D., Smythe, A. M., Murray, J., Anderson-Stewart, P., Kitchen, N., Muirhead, R., Phillips, P., Gray, P., Bigg-Wither, G., Prabakaran, K., Freund, J., Fullham, M., Rule, M., Dalley, D., Meagher, A., Hawkins, N. J. & Smith, G. M., Dec 2000, In: Clinical Cancer Research. 6, 12, p. 4674-4683 10 p.

  Research output: Contribution to journal › Article › peer-review
  6 Scopus citations

• Phase I clinical trial of donor t-helper type 2 cells after immunoablative, reduced intensity allogeneic PBSC transplant

  Fowler, D., Hou, J., Foley, J., Hakim, F., Odom, J., Castro, K., Carter, C., Read, E., Gea-Banacloche, J., Kasten-Sportes, C., Kwak, L., Wilson, W., Levine, B., June, C., Gress, R. & Bishop, M., Jan 1 2002, In: Cytotherapy. 4, 5, p. 429-430 2 p.

  Research output: Contribution to journal › Article › peer-review
  18 Scopus citations

• Phase I Clinical Trial of Costimulated, IL-4 Polarized Donor CD4⁺ T Cells as Augmentation of Allogeneic Hematopoietic Cell Transplantation

  Fowler, D. H., Odom, J., Steinberg, S. M., Chow, C. K., Foley, J., Kogan, Y., Hou, J., Gea-Banacloche, J., Sportes, C., Pavletic, S., Leitman, S., Read, E. J., Carter, C., Kolstad, A., Fox, R., Beatty, G. L., Vonderheide, R. H., Levine, B. L., June, C. H., Gress, R. E. & 1 others, Bishop, M. R., Nov 2006, In: Biology of Blood and Marrow Transplantation. 12, 11, p. 1150-1160 11 p.

  Research output: Contribution to journal › Article › peer-review
  53 Scopus citations

• Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers

  Kantarjian, H. M., Gandhi, V., Kozuch, P., Faderl, S., Giles, F., Cortes, J., O'Brien, S., Ibrahim, N., Khuri, F., Du, M., Rios, M. B., Jeha, S., McLaughlin, P., Plunkett, W. & Keating, M., Mar 15 2003, In: Journal of Clinical Oncology. 21, 6, p. 1167-1173 7 p.

  Research output: Contribution to journal › Article › peer-review
  172 Scopus citations

• Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

  Kantarjian, H., Garcia-Manero, G., O'Brien, S., Faderl, S., Ravandi, F., Westwood, R., Green, S. R., Chiao, J. H., Boone, P. A., Cortes, J. & Plunkett, W., Jan 10 2010, In: Journal of Clinical Oncology. 28, 2, p. 285-291 7 p.

  Research output: Contribution to journal › Article › peer-review
  65 Scopus citations